Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2020
Enanta Pharmaceuticals (NASDAQ:ENTA) will report its fiscal Q1 results on February 8, 2021, after market close. The company's management will host a conference call at 4:30 p.m. ET to discuss the results and provide updates on its R&D pipeline, targeting viral infections and liver diseases. Enanta’s research focuses on diseases like respiratory syncytial virus, hepatitis B, and non-alcoholic steatohepatitis, with funding derived from royalties from its collaboration with AbbVie for hepatitis C virus treatments.
- Ongoing research in multiple viral infection therapies and liver diseases.
- Strong funding from royalties on hepatitis C virus products.
- Diversified clinical pipeline including RSV, HBV, and NASH.
- No significant positive financial metrics reported in the PR.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2020 after the U.S. markets close on February 8, 2021. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.
Conference Call and Webcast Information
To participate in the live conference call, please dial 855-840-0595 in the U.S. or 518-444-4814 for international callers. A replay of the conference call will be available starting at approximately 7:30 p.m. ET on February 8, 2021, through 11:59 p.m. ET on February 12, 2021 by dialing 855-859-2056 from the U.S. or 404-537-3406 for international callers. The passcode for both the live call and the replay is 2854627. A live audio webcast of the call and replay can be accessed by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com.
About Enanta
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). Enanta is also conducting research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).
Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005722/en/
FAQ
When will Enanta Pharmaceuticals report its Q1 financial results?
What is the focus of Enanta's research and development?
How can I participate in Enanta's conference call?
What royalties does Enanta receive?
